# Efficacy and Safety Study of the Fixed-dose Combination of Olmesartan + Indapamide When Compared to the Isolated Drugs in the Treatment of Hypertension.

Study · id `cardio:ct-nct05110898` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05110898](<https://clinicaltrials.gov/study/NCT05110898>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05110898

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 400 participants.

## Technical summary

Registry record NCT05110898. Randomized; single masking; primary purpose treatment. Start 2022-08-01 (anticipated); primary completion 2023-08-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 400 participants (planned count; ClinicalTrials.gov record NCT05110898, source copy `cardio:ctgov-nct05110898-2022-03-21`, retrieved 2026-10-26)
- Planned start: 2022-08-01 (anticipated) (ClinicalTrials.gov record NCT05110898, source copy `cardio:ctgov-nct05110898-2022-03-21`, retrieved 2026-10-26)
- Primary completion: 2023-08-01 (anticipated) (ClinicalTrials.gov record NCT05110898, source copy `cardio:ctgov-nct05110898-2022-03-21`, retrieved 2026-10-26)
- Completion: 2023-10-01 (anticipated) (ClinicalTrials.gov record NCT05110898, source copy `cardio:ctgov-nct05110898-2022-03-21`, retrieved 2026-10-26)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05110898-2022-03-21`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy and Safety Study of the Fixed-dose Combination of Olmesartan + Indapamide When Compared to the Isolated Drugs in the Treatment of Hypertension.
- Acronym: OLINDA
- Condition: Hypertension
- Condition: Hypertension,Essential
- Intervention (Drug): fixed-dose of olmesartan 20mg/40 mg + indapamide 1,5 mg
- Intervention (Drug): Isolated drugs Olmesartan (20 mg or 40 mg) and Indapamide (1,5 mg)
- Lead sponsor: Brainfarma Industria Química e Farmacêutica S/A
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)

## Provenance

Content hash: 4a7f91c93e244f2d8fcd5dc20890ee7190156e806a17b5293e7022664436942c
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
